Cell Therapeutics receives German Federal Joint Committee's final benefit ... pharmabiz.com The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing randomized controlled phase III clinical trial, which compares Pixuvri -rituximab to gemcitabine-rituximab in patients who have ... |
